{"result": "(\"entity\"<|>CYP11B2<|>ORGANIZATION<|>CYP11B2 is an enzyme expressed in the zona glomerular of the adrenal cortex, involved in the synthesis of aldosterone.)\n##\n(\"entity\"<|>ALDOSTERONE<|>ORGANIZATION<|>Aldosterone is a hormone produced in the adrenal cortex that regulates sodium and potassium levels in the body.)\n##\n(\"entity\"<|>ACTH<|>ORGANIZATION<|>Adrenocorticotropic hormone (ACTH) is a hormone that stimulates the adrenal glands to produce cortisol and has a mild effect on aldosterone secretion.)\n##\n(\"entity\"<|>RENIN<|>ORGANIZATION<|>Renin is an enzyme secreted by the kidneys that plays a key role in the regulation of blood pressure and fluid balance.)\n##\n(\"entity\"<|>HYPERALDOSTERONISM<|>EVENT<|>Hyperaldosteronism is a condition characterized by excessive production of aldosterone, leading to hypertension and hypokalemia.)\n##\n(\"entity\"<|>DIURETICS<|>ORGANIZATION<|>Diuretics are medications that promote the elimination of water and salts from the body, often used to treat hypertension.)\n##\n(\"entity\"<|>RENOVASCULAR DISEASE<|>ORGANIZATION<|>Renovascular disease refers to conditions affecting the blood vessels supplying the kidneys, which can lead to secondary hyperaldosteronism.)\n##\n(\"entity\"<|>HARRISON PRINCIPLES OF INTERNAL MEDICINE<|>ORGANIZATION<|>A comprehensive medical textbook that provides guidelines and information on various medical conditions, including hyperaldosteronism.)\n##\n(\"entity\"<|>UPTODATE<|>ORGANIZATION<|>UpToDate is a clinical decision support resource that provides evidence-based information for healthcare professionals.)\n##\n(\"entity\"<|>MANUAL DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>ORGANIZATION<|>A manual that provides guidelines and information on endocrinology and nutrition, including conditions like hyperaldosteronism.)\n##\n(\"relationship\"<|>CYP11B2<|>ALDOSTERONE<|>CYP11B2 is responsible for the synthesis of aldosterone in the zona glomerular of the adrenal cortex<|>8)\n##\n(\"relationship\"<|>ACTH<|>ALDOSTERONE<|>ACTH has a mild stimulating effect on the secretion of aldosterone<|>5)\n##\n(\"relationship\"<|>RENIN<|>HYPERALDOSTERONISM<|>Renin levels are often elevated in cases of hyperaldosteronism, particularly in secondary forms<|>6)\n##\n(\"relationship\"<|>DIURETICS<|>HYPERALDOSTERONISM<|>The use of diuretics can lead to secondary hyperaldosteronism due to fluid and electrolyte imbalances<|>4)\n##\n(\"relationship\"<|>RENOVASCULAR DISEASE<|>HYPERALDOSTERONISM<|>Renovascular disease can cause secondary hyperaldosteronism due to increased renin production<|>7)\n##\n(\"relationship\"<|>HARRISON PRINCIPLES OF INTERNAL MEDICINE<|>HYPERALDOSTERONISM<|>The textbook provides guidelines and information on the diagnosis and management of hyperaldosteronism<|>5)\n##\n(\"relationship\"<|>UPTODATE<|>HYPERALDOSTERONISM<|>UpToDate offers evidence-based information on the diagnosis and treatment of hyperaldosteronism<|>5)\n##\n(\"relationship\"<|>MANUAL DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>HYPERALDOSTERONISM<|>The manual includes information on hyperaldosteronism and its management<|>5)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: zona glomerular bajo el control de tres principales\n                                                                                                                                                 estimuladores: la angiotensina II, el potasio y, en menor medida, la ACTH. Otros factores,\n         COMENTARIO                                                                                                                              en especial, la somatostatina, la heparina, el péptido natriurético auricular y la dopamina,\n                                                                                                                                                 pueden inhibir directamente la síntesis de aldosterona. La secreción de aldosterona y sus\n         La prueba de cribado recomendada para el estudio del paciente con sospecha de hi-                                                       metabolitos intermediarios está restringida a la zona glomerular debido a la expresión se-\n         peraldosteronismo primario es la relación entre la aldosterona plasmática y la ac-                                                      lectiva de la CYP11B2           en esa zona de la corteza suprarrenal.\n         tividad de renina plasmática (ALD/ARP). El valor de corte más aceptado para la re-                                                      La angiotensina II y el potasio estimulan la secreción de aldosterona aumentando la trans-\n         lación ALD/ARP es 30 cuando la aldosterona se presenta como nanogramos por                                                              cripción de CYP11B2 por medio de vías de señalización                          intracelular comunes.\n         decilitro y la actividad de renina plasmática como nanogramos por mililitro por hora.\n         Una limitación de la relación ALD/ARP es que en presencia de valores muy bajos de ARP (p.                                               El efecto de la ACTH sobre la secreción de aldosterona es leve y difiere en las situaciones agu-\n         ej, 0,1 ng/ml/h), la relación ALD/ARP puede ser superior a 30 aunque los valores de aldoste-                                            das y crónicas. Un bolo agudo de ACTH aumenta la secreción de ACTH al estimular las vías\n         rona sean bajos y no sugerentes de hiperaldosteronismo                           (p. ej., 4 ng/dl).                                     iniciales de la esteroidogénesis suprarrenal, pero la concentración circulante no aumenta más\n                                                                                                                                                 de un 10-20% respecto al valor basal. La estimulación continua crónica con ACTH no tiene\n         Existen otras causas diferentes de la presencia de hiperaldosteronismo primario que deben                                               efecto o tiene un efecto inhibidor sobre la producción de aldosterona, posiblemente debido a\n         ser tenidas en cuenta al estudiar al paciente con hipertensión e hipopotasemia. Entre ellas                                             una infrarregulación de la aldosterona por el efecto mineralocorticoide del cortisol.\n         destacan,      por frecuencia, la toma de diuréticos, la               enfermedad renovascular (la ARP estará                           Referencias:\n         elevada), los hipermineralocorticismos no dependientes de aldosterona (en ellos, renina                                                 • Arlt W. Trastornos de la corteza suprarrenal. En: Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscazo J, eds. Harrison\n         y aldosterona estarán suprimidos) y los hiperaldosteronismos secundarios (en ellos, renina y                                            • Principios de Medicina Interna. 19.ª edición en español. México DF: Mc Graw Hill; 2016. p. 2309-29.\n                                                                                                                                                   Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection,\n         aldosterona estarán elevados).                                                                                                            diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101:1889-916.\n                                                                                                                                                 • Lahera Vargas M. Hiperaldosteronismo primario. Manual de Endocrinología y Nutrición. Disponible en: https://manual.seen.es\n         Referencias:                                                                                                                              (última modificación: 25 de noviembre de 2015).\n         • Arlt W. Trastornos de la corteza suprarrenal. En: Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscazo J, eds. Harrison      • Young WF, Jr. Diagnosis of primary aldosteronism. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Literature\n           Principios de Medicina Interna. 19.ª edición en español. México DF: Mc Graw Hill; 2016. p. 2309-29.                                     review current through: Apr. 2019.\n         • Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection,       • Young WF, Jr. Endocrine Hypertension. En: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM, eds Williams Textbook\n           diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101:1889-916.                 of Endocrinology. 13.ª ed. Philadelphia: Elsevier; 2016. p.\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}